X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.040
-0.270 (-6.26%)
At close: Mar 27, 2026, 4:00 PM EDT
4.000
-0.040 (-0.99%)
After-hours: Mar 27, 2026, 4:37 PM EDT
X4 Pharmaceuticals Revenue
In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth. X4 Pharmaceuticals had revenue of $2.57M in the quarter ending December 31, 2025, with 79.08% growth.
Revenue (ttm)
$35.11M
Revenue Growth
+1,273.21%
P/S Ratio
10.46
Revenue / Employee
$780,289
Employees
45
Market Cap
367.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 170.16M |
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 66.98M |
| XOMA Royalty | 52.15M |
| Lineage Cell Therapeutics | 14.56M |
| PureTech Health | 6.39M |
XFOR News
- 12 days ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 26 days ago - X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
- 26 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 7 weeks ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha